<DOC>
	<DOCNO>NCT00474994</DOCNO>
	<brief_summary>RATIONALE : Sunitinib may stop growth tumor cell block enzymes need cell growth block blood flow tumor . PURPOSE : This phase II trial study well sunitinib work treat patient metastatic , locally advanced , locally recurrent sarcoma .</brief_summary>
	<brief_title>Sunitinib Treating Patients With Metastatic , Locally Advanced , Locally Recurrent Sarcomas</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate ( complete response partial response ) patient metastatic , locally advanced , locally recurrent non-gastrointestinal stromal tumor sarcoma treat sunitinib malate . Secondary - Determine 16- 24-week progression-free survival rate ( complete response , partial response , stable disease ) patient treat drug . - Determine overall survival patient treated drug . - Correlate clinical response change soluble angiogenesis mediator level patient treat drug . - Determine tumor maximum standardized uptake value fludeoxyglucose F 18-PET scan patient treat drug . OUTLINE : This multicenter study . Patients stratify neoplastic subtype ( vascular connective tissue neoplasm , leiomyosarcoma , dermatofibrosarcoma protuberans , chordoma , desmoid tumor vs high-grade undifferentiated pleomorphic sarcoma [ i.e. , malignant fibrous histiocytoma ( include myxofibrosarcoma ) ] , nongastrointestinal connective tissue tumor [ include carcinosarcoma ] ) . Patients receive oral sunitinib malate daily day 1-28 . Courses repeat every 4 week absence disease progression unacceptable toxicity . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Fibromatosis , Aggressive</mesh_term>
	<mesh_term>Histiocytoma</mesh_term>
	<mesh_term>Histiocytoma , Benign Fibrous</mesh_term>
	<mesh_term>Histiocytoma , Malignant Fibrous</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm connective tissue neoplasm , include follow neoplastic subtypes : Vascular connective tissue neoplasm Leiomyosarcoma Dermatofibrosarcoma protuberans Chordoma Desmoid tumor Highgrade undifferentiated pleomorphic sarcoma ( e.g. , malignant fibrous histiocytoma [ include myxofibrosarcoma ] ) Carcinosarcomas ( e.g. , malignant mixed Müllerian tumor ) Giant hemangiomata Kaposi sarcoma Metastatic , locally advanced , locally recurrent disease Measurable disease Tumor lesions previously irradiate area may consider measurable provided evidence growth attribute necrosis bleed No gastrointestinal stromal tumor sarcomas Prior standard neoadjuvant adjuvant systemic therapy require patient follow diagnosis : Rhabdomyosarcoma Osteosarcoma Ewing sarcoma No untreated brain metastasis , spinal cord compression , evidence symptomatic brain metastasis leptomeningeal disease document screen CT scan MRI PATIENT CHARACTERISTICS : ECOG performance status 02 Absolute neutrophil count ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Bilirubin ≤ 1.5 mg/dL PT INR ≤ 1.5 AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 1.5 mg/dL Calcium ≤ 12 mg/dL Blood glucose &lt; 150 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception prior , , 28 day completion study therapy Other malignancy allow provided sarcoma primary disease require systemic therapy Able swallow oral medication No disease illness within past 6 month , include follow : Myocardial infarction Severe unstable angina Coronary peripheral artery bypass graft Symptomatic congestive heart failure Cerebrovascular accident transient ischemic attack Pulmonary embolism No evidence bleed diathesis No ongoing cardiac dysrhythmias &gt; grade 2 No uncontrolled hypertension , define blood pressure &gt; 150/100 mm Hg despite optimal medical therapy Left ventricular ejection fraction ≥ 50 % echocardiogram MUGA scan No psychiatric illness social situation would preclude study compliance No preexisting thyroid abnormality , define abnormal thyroid function test despite medication No prolong QTc interval ( i.e. , QTc &gt; 450 msec male QTc &gt; 470 msec female ) baseline EKG No hemorrhage ≥ grade 3 past 4 week PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy No prior sunitinib malate No 3 prior cytotoxic chemotherapy regimens metastatic disease Adjuvant chemotherapy sarcoma complete &gt; 1 year prior study entry consider line prior treatment At least 2 week since prior cytotoxic chemotherapy At least 6 week since prior carmustine mitomycin C At least 1 week since prior biological therapy small molecule kinase inhibitor At least 3 week since prior radiotherapy ( except palliative radiotherapy specific site ) Prior palliative radiotherapy allow provide consider medically necessary target lesion assess More 4 week since prior major surgery Concurrent major surgery allow provide study drug stop 2 week surgery resume 2 week surgery Concurrent palliative radiotherapy ( e.g. , focal radiotherapy bony metastasis relieve bone pain ) allow No concurrent investigational drug No concurrent participation another clinical trial No concurrent therapeutic anticoagulation ( e.g. , warfarin ) Prophylactic anticoagulation ( i.e. , lowdose warfarin ) venous arterial access device allow provided requirement PT INR meet No concurrent approve investigational anticancer agent treatment , include chemotherapy , biological response modifier therapy , hormonal therapy , immunotherapy Concurrent hormone replacement therapy adrenal insufficiency allow No concurrent antiepileptic drug ( e.g. , phenytoin , carbamazepine , phenobarbital ) No concurrent rifampin , theophylline , ketoconazole , Hypericum perforatum ( St. John 's wort )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>chondrosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
	<keyword>localize adult malignant fibrous histiocytoma bone</keyword>
	<keyword>metastatic adult malignant fibrous histiocytoma bone</keyword>
	<keyword>recurrent adult malignant fibrous histiocytoma bone</keyword>
	<keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>dermatofibrosarcoma protuberans</keyword>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>uterine leiomyosarcoma</keyword>
	<keyword>stage III uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>desmoid tumor</keyword>
	<keyword>adult angiosarcoma</keyword>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>uterine carcinosarcoma</keyword>
	<keyword>endometrial stromal sarcoma</keyword>
	<keyword>fibrosarcomatous osteosarcoma</keyword>
	<keyword>chondrosarcomatous osteosarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult extraskeletal chondrosarcoma</keyword>
	<keyword>adult extraskeletal osteosarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult malignant hemangiopericytoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>adult desmoplastic small round cell tumor</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>anaplastic osteosarcoma</keyword>
	<keyword>mixed osteosarcoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>osteoblastic osteosarcoma</keyword>
	<keyword>telangiectatic osteosarcoma</keyword>
	<keyword>classic Kaposi sarcoma</keyword>
	<keyword>immunosuppressive treatment relate Kaposi sarcoma</keyword>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
</DOC>